Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Earnings Report 5.786 USD Q2 2025 Earnings Release 08/07/2025 Earnings Report 6.286 USD Q3 2025 Earnings Release 10/30/2025 Earnings Report 7.208 USD Q4 2025 Earnings Release 02/11/2026 Earnings ...

Recently, Eli Lilly (LLY) revealed that they saw some concerning indicators for their GLP-1 drug in December, which might have been the culprit behind them missing their Q4 revenue guidance by $400M.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare ... For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates of $4.4 billion.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...